Since then, HER2-targeted drugs have occupied a place in the fields of mAbs (trastuzumab, pertuzumab, margetuximab, biosimilars...), TKIs (lapatinib, neratinib, tucatinib, pyrotinib, afatinib, dacomitinib...), ADCs (T-DM1, T-DXd, RC48, A166, SHR-A1811...), and later bsAbs (anbenitamab, zanidatamab, TQB2930...) and bsADCs (JSKN003, ZW49, HER2/HER3 BsADC...), which have flourished in multiple areas and entered a new situation in various tumors such as breast cancer, gastric cancer, and non-small cell lung cancer. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.